Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. [electronic resource]

By:

Minagawa, Yukihisa

Contributor(s):

Kigawa, Junzo
Kanamori, Yasunobu
Itamochi, Hiroaki
Terakawa, Naoki
Okada, Makoto
Kitada, Fuminori

Producer: 20060627Description: 495-8 p. digitalISSN:

0090-8258

Subject(s):

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols -- adverse effects
Carboplatin -- administration & dosage
Cisplatin -- administration & dosage
Docetaxel
Drug Administration Schedule
Feasibility Studies
Female
Humans
Middle Aged
Neoplasm Staging
Ovarian Neoplasms -- drug therapy
Taxoids -- administration & dosage

Online resources:

Available from publisher's website

In: Gynecologic oncology vol. 101

Tags from this library: No tags from this library for this title. Log in to add tags.

Star ratings

Cancel rating. Average rating: 0.0 (0 votes)

Holdings ( 0 )
Title notes ( 1 )
Comments ( 0 )

No physical items for this record

Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial

There are no comments on this title.

Browse results Close

Back to results

1 Parkia biglobosa seeds possess anti platelet activity.
by Rendu, F
2 Platelet procoagulant activity is independent of aggregation.
by Rendu, F
3 A novel nonsense mutation in the antithrombin III gene (Cys-4-->stop) causing recurrent venous thrombosis.
by Saleun, S
4 Baculovirus vector requires electrostatic interactions including heparan sulfate for efficient gene transfer in mammalian cells.
by Duisit, G
5 Influence of a 12-hour, 22 degrees C holding period for buffy coats on the preparation of platelet concentrates stored in plasma.
by Boeri, N
6 Functional implications of tyrosine protein phosphorylation in platelets. Simultaneous studies with different agonists and inhibitors.
by Bachelot, C
7 Construction of a 780-kb PAC, BAC, and cosmid contig encompassing the minimal critical deletion involved in B cell chronic lymphocytic leukemia at 13q14.3.
by Bouyge-Moreau, I

Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer.

APA

Minagawa Y., Kigawa J., Kanamori Y., Itamochi H., Terakawa N., Okada M. & Kitada F. (20060627). Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. : Gynecologic oncology.

Chicago

Minagawa Yukihisa, Kigawa Junzo, Kanamori Yasunobu, Itamochi Hiroaki, Terakawa Naoki, Okada Makoto and Kitada Fuminori. 20060627. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. : Gynecologic oncology.

Harvard

Minagawa Y., Kigawa J., Kanamori Y., Itamochi H., Terakawa N., Okada M. and Kitada F. (20060627). Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. : Gynecologic oncology.

MLA

Minagawa Yukihisa, Kigawa Junzo, Kanamori Yasunobu, Itamochi Hiroaki, Terakawa Naoki, Okada Makoto and Kitada Fuminori. Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. : Gynecologic oncology. 20060627.

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)

Exporting to Dublin Core...

Simple DC-RDF

OAI-DC

SRW-DC